Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting Receptor Tyrosine Kinase VEGFR-2 in Hepatocellular Cancer: Rational Design, Synthesis and Biological Evaluation of 1,2-Disubstituted Benzimidazoles
Heba T. Abdel‐Mohsen, Mona A. Abdullaziz, Ahmed M. El Kerdawy, et al.
Molecules (2020) Vol. 25, Iss. 4, pp. 770-770
Open Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment
Asieh Emami Nejad, Simin Najafgholian, Alireza Rostami, et al.
Cancer Cell International (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 514
Design, Synthesis, Docking, DFT, MD Simulation Studies of a New Nicotinamide-Based Derivative: In Vitro Anticancer and VEGFR-2 Inhibitory Effects
Eslam B. Elkaeed, Reda G. Yousef, Hazem Elkady, et al.
Molecules (2022) Vol. 27, Iss. 14, pp. 4606-4606
Open Access | Times Cited: 99
Receptor tyrosine kinase inhibitors in cancer
Nasim Ebrahimi, Elmira Fardi, Hajarossadat Ghaderi, et al.
Cellular and Molecular Life Sciences (2023) Vol. 80, Iss. 4
Open Access | Times Cited: 64
Receptor-based pharmacophore modeling, molecular docking, synthesis and biological evaluation of novel VEGFR-2, FGFR-1, and BRAF multi-kinase inhibitors
Heba T. Abdel‐Mohsen, Marwa Ibrahim, Amira M. Nageeb, et al.
BMC Chemistry (2024) Vol. 18, Iss. 1
Open Access | Times Cited: 17
Benzimidazole based derivatives as anticancer agents: Structure activity relationship analysis for various targets
Garvit Satija, Barkha Sharma, Anish Madan, et al.
Journal of Heterocyclic Chemistry (2021) Vol. 59, Iss. 1, pp. 22-66
Closed Access | Times Cited: 83
Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma
Ibrahim H. Eissa, M.K. Ibrahim, Ahmed M. Metwaly, et al.
Bioorganic Chemistry (2020) Vol. 107, pp. 104532-104532
Closed Access | Times Cited: 78
Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers
Mohammed M. Alanazi, Ibrahim H. Eissa, Nawaf A. Alsaif, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2021) Vol. 36, Iss. 1, pp. 1760-1782
Open Access | Times Cited: 78
Recent advances in nitrogen-containing heterocyclic compounds as receptor tyrosine kinase inhibitors for the treatment of cancer: Biological activity and structural activity relationship
Keshav Taruneshwar Jha, Abhimannu Shome, Chahat, et al.
Bioorganic Chemistry (2023) Vol. 138, pp. 106680-106680
Closed Access | Times Cited: 33
Thymus Vulgaris Oil Nanoemulsion: Synthesis, Characterization, Antimicrobial and Anticancer Activities
Ahmed S. Doghish, Amr M. Shehabeldine, Hesham N. Elmahdy, et al.
Molecules (2023) Vol. 28, Iss. 19, pp. 6910-6910
Open Access | Times Cited: 28
Benzimidazole-oxindole hybrids as multi-kinase inhibitors targeting melanoma
Rasha M. Allam, Ahmed M. El Kerdawy, Ahmed Gouda, et al.
Bioorganic Chemistry (2024) Vol. 146, pp. 107243-107243
Closed Access | Times Cited: 15
Recent advances in, and challenges of, anti-angiogenesis agents for tumor chemotherapy based on vascular normalization
Kai Wang, Qinhua Chen, Nanxin Liu, et al.
Drug Discovery Today (2021) Vol. 26, Iss. 11, pp. 2743-2753
Closed Access | Times Cited: 44
Discovery of new 3-methylquinoxalines as potential anti-cancer agents and apoptosis inducers targeting VEGFR-2: design, synthesis, and in silico studies
Mohammed M. Alanazi, Alaa Elwan, Nawaf A. Alsaif, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2021) Vol. 36, Iss. 1, pp. 1732-1750
Open Access | Times Cited: 43
Design, Synthesis, and Molecular Modeling Studies of a Novel Benzimidazole as an Aromatase Inhibitor
Ulviye Acar Çevik, İsmail Çeli̇k, Jaime Mella, et al.
ACS Omega (2022) Vol. 7, Iss. 18, pp. 16152-16163
Open Access | Times Cited: 29
Rational design and synthesis of novel quinazolinone N-acetohydrazides as type II multi-kinase inhibitors and potential anticancer agents
Somaia S. Abd El‐Karim, Yasmin M. Syam, Ahmed M. El Kerdawy, et al.
Bioorganic Chemistry (2023) Vol. 142, pp. 106920-106920
Closed Access | Times Cited: 18
Quinazoline‐oxindole hybrids as angiokinase inhibitors and anticancer agents: Design, synthesis, biological evaluation, and molecular docking studies
Yasmin M. Syam, Somaia S. Abd El‐Karim, Heba T. Abdel‐Mohsen
Archiv der Pharmazie (2024) Vol. 357, Iss. 10
Closed Access | Times Cited: 8
Benzimidazole‐oxindole hybrids: A novel class of selective dual CDK2 and GSK‐3β inhibitors of potent anticancer activity
Heba T. Abdel‐Mohsen, Yasmin M. Syam, Mahmoud S. Abd El‐Ghany, et al.
Archiv der Pharmazie (2024) Vol. 357, Iss. 10
Closed Access | Times Cited: 8
Design, Synthesis and Biological Assessment of N′-(2-Oxoindolin-3-ylidene)-6-methylimidazo[2,1-b]thiazole-5-carbohydrazides as Potential Anti-Proliferative Agents toward MCF-7 Breast Cancer
Najla A. Alshaye, Mohamed K. Elgohary, Mahmoud S. Elkotamy, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 2, pp. 216-216
Open Access | Times Cited: 7
Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors
Heba T. Abdel‐Mohsen, Mohamed A. Omar, Ahmed M. El Kerdawy, et al.
European Journal of Medicinal Chemistry (2019) Vol. 179, pp. 707-722
Closed Access | Times Cited: 52
Pyridine‐derived VEGFR‐2 inhibitors: Rational design, synthesis, anticancer evaluations, in silico ADMET profile, and molecular docking
Nashwa M. Saleh, Adel A.‐H. Abdel‐Rahman, Asmaa M. Omar, et al.
Archiv der Pharmazie (2021) Vol. 354, Iss. 8
Closed Access | Times Cited: 41
Benzimidazole‐based protein kinase inhibitors: Current perspectives in targeted cancer therapy
Alaa M. Ali, Samar S. Tawfik, Amany S. Mostafa, et al.
Chemical Biology & Drug Design (2022) Vol. 100, Iss. 5, pp. 656-673
Closed Access | Times Cited: 23
Antiangiogenic potential of phytochemicals from Clerodendrum inerme (L.) Gaertn investigated through in silico and quantum computational methods
Nusrath Yasmeen, Anis Ahmad Chaudhary, Salauddin Khan, et al.
Molecular Diversity (2024) Vol. 29, Iss. 1, pp. 215-239
Closed Access | Times Cited: 4
Diphenyl urea‐benzylidene acetohydrazide hybrids as fibroblast growth factor receptor 1 inhibitors and anticancer agents
Heba T. Abdel‐Mohsen, Amira M. Nageeb, Iman A. Y. Ghannam
Drug Development Research (2024) Vol. 85, Iss. 6
Closed Access | Times Cited: 4
Novel 5,6-dichlorobenzimidazole derivatives as dual BRAFWT and BRAFV600E inhibitors: design, synthesis, anti-cancer activity and molecular dynamics simulations
Ahmed Temirak, Ahmed M. El Kerdawy, Amira M. Nageeb, et al.
BMC Chemistry (2025) Vol. 19, Iss. 1
Open Access
In Vitro and In Silico Evaluation of Anticancer Potential and Apoptotic Activity of Benzimidazole‐Based Compounds
Sabri Messaoudi, Fahad M. Alminderej, Hind R. Almuhaylan, et al.
ChemistrySelect (2025) Vol. 10, Iss. 8
Closed Access
Bicyclic 2-Aminopyrimidine Derivatives as Potent VEGFR-2 Inhibitors and Apoptosis Inducers: Structure-Guided Design, Synthesis, Anticancer Assessment, and In-Silico Exploration
Arshma Siddique, Samir I. Shaheen, Iftikhar Ali, et al.
European Journal of Medicinal Chemistry (2025) Vol. 293, pp. 117726-117726
Closed Access
Page 1 - Next Page

Scroll to top